HOW NGS CHANGES
CANCER TREATMENT
Without NGS, the same chemotherapy regimen gets prescribed regardless of the molecular driver. With it, a patient with an EGFR mutation gets a matched oral tablet instead of IV chemotherapy. The test makes that choice possible.
What NGS Findings Drive Clinically
The specific clinical decisions that NGS findings drive across the treatment journey.
Targeted Therapy Selection
EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, NTRK, HER2 and others across cancer types each have at least one approved matched therapy. NGS identifies which are present.
Immunotherapy Eligibility
Comprehensive panels include TMB and MSI assessment. Both predict checkpoint inhibitor benefit across cancer types. Both would be missed by targeted single-gene testing.
Clinical Trial Eligibility
Many Phase I and II trials are biomarker-selected. NGS results determine which basket trials and targeted programmes a patient qualifies for -- including for cancer types without approved matched therapies.
Germline Risk Identification
Pathogenic BRCA1/2, Lynch syndrome gene variants, and others found in tumour testing may prompt germline testing with family implications.
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About What Your NGS Results Mean for Treatment?
CancerFax reviews your genomic profiling results and connects you with oncologists experienced in molecular-guided treatment decisions.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.